Joel H. Kaufman
2020
In 2020, Joel H. Kaufman earned a total compensation of $326.3K as Chief Business Officer at Navidea Biopharmaceuticals, a 19% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $55,381 |
|---|---|
| Option Awards | $39,600 |
| Salary | $226,042 |
| Other | $5,324 |
| Total | $326,347 |
Kaufman received $226K in salary, accounting for 69% of the total pay in 2020.
Kaufman also received $55.4K in non-equity incentive plan, $39.6K in option awards and $5.3K in other compensation.
Rankings
In 2020, Joel H. Kaufman's compensation ranked 11,976th out of 13,090 executives tracked by ExecPay. In other words, Kaufman earned more than 8.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,976 out of 13,090 | 9th |
Division Manufacturing | 5,121 out of 5,617 | 9th |
Major group Chemicals And Allied Products | 2,087 out of 2,248 | 7th |
Industry group Drugs | 1,817 out of 1,948 | 7th |
Industry In Vitro and In Vivo Diagnostic Substances | 52 out of 60 | 13th |
Source: SEC filing on August 2, 2021.
Kaufman's colleagues
We found three more compensation records of executives who worked with Joel H. Kaufman at Navidea Biopharmaceuticals in 2020.
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019